EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

CLDN18.2 in Gastric Cancer: Current Therapeutic Landscape and Future Perspectives

Fei Zhang, Ukyo Okazaki iD, Izuma Nakayama iD, Kohei Shitara iD

Journal of Gastric Cancer · 2026 · 26 (1) · 127

DOI: 10.5230/jgc.2026.26.e10 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Gastric Cancer, 2026. Verfasst von Fei Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Claudins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Claudin 18.2 (CLDN18.2), a tight junction protein selectively expressed in normal gastric epithelium and widely retained during carcinogenesis, has emerged as a promising therapeutic target for advanced gastric cancer (AGC). SPOTLIGHT and GLOW trials evaluated the anti-CLDN18.2 monoclonal antibody (mAb) zolbetuximab in combination with first-line chemotherapy, and established CLDN18.2 as a therapeutic target, initiating a paradigm shift toward a biomarker-driven treatment approach in AGC. In addition, from zolbetuximab to a diverse pipeline of promising high-affinity mAbs, bispecific antibodies, antibody-drug conjugates and chimeric antigen receptor T cells, this target has established a new and highly effective therapeutic avenue for CLDN18.2-expressing AGC. Therefore, as research progresses, CLDN18.2-targeted therapy is poised to become a cornerstone of treatment across multiple disease stages and cancer types. This review describes the biological role of CLDN18.2 in normal gastric epithelium and gastric carcinogenesis and summarizes the current therapeutic landscape and future perspectives targeting CLDN18.2 in AGC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsClaudinsHumansBiomarkers, TumorAntibodies, MonoclonalMolecular Targeted Therapy

Stichwörter der Autor:innen

BiomarkerClaudinsGastric cancerTargeted therapy

Substanzen

ClaudinsCLDN18 protein, humanBiomarkers, TumorAntibodies, Monoclonalzolbetuximab

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. iznakaya@east.ncc.go.jp.

ORCID-Profile: Ukyo Okazaki, Izuma Nakayama, Kohei Shitara

Zitieren

APA

Zhang, F., Okazaki, U., Nakayama, I., & Shitara, K. (2026). CLDN18.2 in Gastric Cancer: Current Therapeutic Landscape and Future Perspectives. Journal of Gastric Cancer, 26(1), 127. https://doi.org/10.5230/jgc.2026.26.e10

Vancouver

Zhang F, Okazaki U, Nakayama I, Shitara K. CLDN18.2 in Gastric Cancer: Current Therapeutic Landscape and Future Perspectives. Journal of Gastric Cancer. 2026;26(1):127. doi:10.5230/jgc.2026.26.e10

BibTeX
@article{Zhang2026,
  author = {Zhang, Fei and Okazaki, Ukyo and Nakayama, Izuma and Shitara, Kohei},
  title = {CLDN18.2 in Gastric Cancer: Current Therapeutic Landscape and Future Perspectives},
  journal = {Journal of Gastric Cancer},
  year = {2026},
  volume = {26},
  number = {1},
  pages = {127},
  doi = {10.5230/jgc.2026.26.e10}
}
Kostenlos starten →